578 - Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes: a New-User, Active-Comparator Analysis Using the National COVID Cohort Collaborative (N3C) Electronic Health Record Database. This research was supported in part by the Intramural/Extramural research program of the National Center for Advancing Translational Science, NIH.

Presenting Author(s)

• 

  Carolyn Bramante, MD, MPH

  Assistant Professor, General Internal Medicine
  University of Minnesota
  Minneapolis, MN, United States

  Slides

Co-Author(s)

• TS

  Til Sturmer, MD, PhD

  University of North Carolina, Chapel Hill
  Chapel Hill, North Carolina, United States
• JH

  Jared Huling, PhD

  University of Minnesota
  Minneapolis, Minnesota, United States
• JB

  John Buse, MD, PhD

  University of North Carolina, Chapel Hill
  Chapel Hill, North Carolina, United States
• SJ

  Steve Johnson, PhD

  University of Minnesota
  Minneapolis, Minnesota, United States
• CL

  Christopher Lindsell, PhD

  Duke University
  Durham, North Carolina, United States
• TS

  Thomas Stewart, PhD

  University of Virginia
  Charlottesville, Virginia, United States
• DS

  David Sahner, MD

  National Institute of Health
  Bethesda, Maryland, United States
• SD

  Sarah Dunsmore, PhD

  National Institute of Health
  Bethesda, Maryland, United States
• ET

  Eric Topol, MD, PhD

  Scripps Research
  San Diego, California, United States